| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3269901 | HPB | 2011 | 9 Pages |
Abstract
Leptin inhibits HCC cell growth in vitro via a p38-MAPK-dependent signalling pathway. Identifying similar effects on tumour growth in vivo may provide an attractive therapeutic target for slowing HCC progression.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Kyle J. Thompson, Kwan N. Lau, Sarah Johnson, John B. Martinie, David A. Iannitti, Iain H. McKillop, David Sindram,